Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism beyond Atrial Fibrillation

다국어 초록 (Multilingual Abstract)

Non-Vitamin K antagonist oral anticoagulants (NOACs) have been extensively investigated in medical conditions at high risk of venous or arterial thrombosis other than atrial fibrillation (AF), including hip or knee arthroplasty, acute venous thromboembolism (VTE), cancer-associated VTE, acute coronary syndrome (ACS), stable atherosclerotic vascular disease, chronic heart failure, and embolic stroke of undetermined source (ESUS). Two large ESUS trials failed to show the benefit of rivaroxaban or dabigatran, and large randomized controlled trial (RCT) data of NOACs are lacking for another potential candidates of patent foramen ovale-related stroke, acute ischemic stroke, and cerebral venous thrombosis. On the other hand, high quality evidences of NOACs have been compiled for VTE prophylaxis after hip or knee arthroplasty, acute VTE, cancer-associated VTE, and concomitant ACS and AF, which have been reflected in clinical practice guidelines.
In addition, RCTs showed the benefit of very low dose rivaroxaban in combination with antiplatelet therapy in patients with ACS and in those with stable cardiovascular disease. This article summarizes the accumulated evidences of NOACs in cardiovascular diseases beyond AF, and aims to inform healthcare providers of optimal regimens tailored to individual medical conditions and help investigators design future clinical trials.

참고문헌 (Reference)

1 Schulman S, "Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis" 129 : 764-772, 2014

2 Kamel H, "The AtRial cardiopathy and antithrombotic drugs in prevention after cryptogenic stroke randomized trial: rationale and methods" 14 : 207-214, 2019

3 Fuji T, "Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial" 134 : 1198-1204, 2014

4 Eikelboom JW, "Rivaroxaban with or without aspirin in stable cardiovascular disease" 377 : 1319-1330, 2017

5 Anand SS, "Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial" 391 : 219-229, 2018

6 Pengo V, "Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome" 132 : 1365-1371, 2018

7 Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation" 365 : 883-891, 2011

8 Mega JL, "Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial" 374 : 29-38, 2009

9 Turpie AG, "Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial" 373 : 1673-1680, 2009

10 Lassen MR, "Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty" 358 : 2776-2786, 2008

11 Eriksson BI, "Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty" 358 : 2765-2775, 2008

12 Kasner SE, "Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial" 17 : 1053-1060, 2018

13 Zannad F, "Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease" 379 : 1332-1342, 2018

14 Mega JL, "Rivaroxaban in patients with a recent acute coronary syndrome" 366 : 9-19, 2012

15 Cohen AT, "Rivaroxaban for thromboprophylaxis in acutely ill medical patients" 368 : 513-523, 2013

16 Turpie AG, "Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: pooled analysis of four studies" 105 : 444-453, 2011

17 Hart RG, "Rivaroxaban for stroke prevention after embolic stroke of undetermined source" 378 : 2191-2201, 2018

18 Lee M, "Risk-benefit profile of warfarin versus aspirin in patients with heart failure and sinus rhythm: a meta-analysis" 6 : 287-292, 2013

19 Ferro JM, "Rationale, design, and protocol of a randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous thrombosis" 13 : 766-770, 2018

20 Gibson CM, "Prevention of bleeding in patients with atrial fibrillation undergoing PCI" 375 : 2423-2434, 2016

21 Falck-Ytter Y, "Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines" 141 (141): e278-e325, 2012

22 Kahn SR, "Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines" 141 (141): e195S-e226S, 2012

23 Mas JL, "Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke" 377 : 1011-1021, 2017

24 RE-MOBILIZE Writing Committee, "Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery" 24 : 1-9, 2009

25 EINSTEIN–PE Investigators, "Oral rivaroxaban for the treatment of symptomatic pulmonary embolism" 366 : 1287-1297, 2012

26 EINSTEIN Investigators, "Oral rivaroxaban for symptomatic venous thromboembolism" 363 : 2499-2510, 2010

27 Mendonça MD, "Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis: a series of 15 patients" 10 : 1115-1118, 2015

28 Eriksson BI, "Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATEII*): a randomised, double-blind, non-inferiority trial" 105 : 721-729, 2011

29 Eriksson BI, "Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial" 5 : 2178-2185, 2007

30 Agnelli G, "Oral apixaban for the treatment of acute venous thromboembolism" 369 : 799-808, 2013

31 Geisbüsch C, "Novel factor Xa inhibitor for the treatment of cerebral venous and sinus thrombosis: first experience in 7 patients" 45 : 2469-2471, 2014

32 Mohammad Wasay, "New Oral Anticoagulants versus Warfarin for Cerebral Venous Thrombosis: A Multi-Center, Observational Study" 대한뇌졸중학회 21 (21): 220-223, 2019

33 "NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): cancer-associated venous thromboembolic disease version 1" National Comprehensive Cancer Network

34 Blom JW, "Malignancies, prothrombotic mutations, and the risk of venous thrombosis" 293 : 715-722, 2005

35 Christersson C, "Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction" 3 : 2245-2253, 2005

36 Réganon E, "Inflammation, fibrinogen and thrombin generation in patients with previous myocardial infarction" 87 : 740-745, 2002

37 Hull RD, "Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial" 153 : 8-18, 2010

38 Gibson CM, "Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically ill patients: an APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban)" 135 : 648-655, 2017

39 Schulman S, "Extended use of dabigatran, warfarin, or placebo in venous thromboembolism" 368 : 709-718, 2013

40 Cohen AT, "Extended thromboprophylaxis with betrixaban in acutely ill medical patients" 375 : 534-544, 2016

41 Kakkar AK, "Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial" 372 : 31-39, 2008

42 Vranckx P, "Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: rationale and design of the ENTRUST-AF PCI trial" 196 : 105-112, 2018

43 Ferro JM, "European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis: endorsed by the European Academy of Neurology" 2 : 195-221, 2017

44 Hart RG, "Embolic strokes of undetermined source: the case for a new clinical construct" 13 : 429-438, 2014

45 Ntaios G, "Efficacy and safety of rivaroxaban versus aspirin in embolic stroke of undetermined source and carotid atherosclerosis" 50 : 2477-2485, 2019

46 Fuji T, "Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V" 13 : 27-, 2015

47 Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation" 369 : 2093-2104, 2013

48 Hokusai-VTE Investigators, "Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism" 369 : 1406-1415, 2013

49 Kawai Y, "Edoxaban versus enoxaparin for the prevention of venous thromboembolism after total knee or hip arthroplasty: pooled analysis of coagulation biomarkers and primary efficacy and safety endpoints from two phase 3 trials" 14 : 48-, 2016

50 Raskob GE, "Edoxaban for the treatment of cancer-associated venous thromboembolism" 378 : 615-624, 2018

51 Cannon CP, "Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation" 377 : 1513-1524, 2017

52 Saposnik G, "Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association" 42 : 1158-1192, 2011

53 Mazzolai L, "Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function" 39 : 4208-4218, 2018

54 Oldgren J, "Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial" 32 : 2781-2789, 2011

55 Schulman S, "Dabigatran versus warfarin in the treatment of acute venous thromboembolism" 361 : 2342-2352, 2009

56 Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation" 361 : 1139-1151, 2009

57 Friedman RJ, "Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials" 126 : 175-182, 2010

58 Kate M, "Dabigatran therapy in acute ischemic stroke patients without atrial fibrillation" 46 : 2685-2687, 2015

59 Diener HC, "Dabigatran for prevention of stroke after embolic stroke of undetermined source" 380 : 1906-1917, 2019

60 Ng KH, "Dabigatran following acute transient ischemic attack and minor stroke II (DATAS II)" 12 : 910-914, 2017

61 Eriksson BI, "Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial" 370 : 949-956, 2007

62 Young AM, "Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)" 36 : 2017-2023, 2018

63 Ardissino D, "Coagulation activation and long-term outcome in acute coronary syndromes" 102 : 2731-2735, 2003

64 Ohman EM, "Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial" 389 : 1799-1808, 2017

65 Greenberg B, "Association of rivaroxaban with thromboembolic events in patients with heart failure, coronary disease, and sinus rhythm: a post hoc analysis of the COMMANDERHF Trial" 4 : 515-523, 2019

66 McBane RD, "Apixaban, dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE trial" 132 (132): 421-, 2018

67 APPRAISE Steering Committee, "Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial" 119 : 2877-2885, 2009

68 Alexander JH, "Apixaban with antiplatelet therapy after acute coronary syndrome" 365 : 699-708, 2011

69 Goldhaber SZ, "Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients" 365 : 2167-2177, 2011

70 Lassen MR, "Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised doubleblind trial" 375 : 807-815, 2010

71 Lassen MR, "Apixaban versus enoxaparin for thromboprophylaxis after hip replacement" 363 : 2487-2498, 2010

72 Lassen MR, "Apixaban or enoxaparin for thromboprophylaxis after knee replacement" 361 : 594-604, 2009

73 Connolly SJ, "Apixaban in patients with atrial fibrillation" 364 : 806-817, 2011

74 Geisler T, "Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): rationale and study design" 12 : 985-990, 2017

75 Rao SK, "Apixaban for the treatment of cerebral venous thrombosis: a case series" 381 : 318-320, 2017

76 Agnelli G, "Apixaban for extended treatment of venous thromboembolism" 368 : 699-708, 2013

77 McBane Ii R, "Apixaban and dalteparin in active malignancy associated venous thromboembolism: the ADAM VTE trial" 117 : 1952-1961, 2017

78 Kearon C, "Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report" 149 : 315-352, 2016

79 Lopes RD, "Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation" 380 : 1509-1524, 2019

80 January CT, "2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society" 74 : 104-132, 2019

81 Lip GYH, "2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)" 21 : 192-193, 2019

82 Ibanez B, "2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with STsegment elevation of the European Society of Cardiology (ESC)" 39 : 119-177, 2018

83 Kirchhof P, "2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS" 37 : 2893-2962, 2016

84 Amsterdam EA, "2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines" 130 : e344-e426, 2014